New agents on the horizon in hepatocellular carcinoma

Therapeutic Advances in Medical Oncology

Volumn 5, Issue 1, 2013, Pages 41-50

  Zhu, Andrew X ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

bevacizumab; brivanib; EGFR inhibitors; everolimus; hepatocellular carcinoma; linifanib; Met inhibitors; sorafenib; sunitinib; targeted agents

Indexed keywords

ANTINEOPLASTIC AGENT; BELINOSTAT; BEVACIZUMAB; BRIVANIB ALANINATE; CABOZANTINIB; CEDIRANIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; LAPATINIB; LENVATINIB; LINIFANIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NEW DRUG; ORANTINIB; PAZOPANIB; PLACEBO; RAMUCIRUMAB; RAPAMYCIN; SCATTER FACTOR; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; BLEEDING; BLOOD TOXICITY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; EDEMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPONATREMIA; HYPOPIGMENTATION; INFECTION; INFUSION RELATED REACTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALAISE; MAXIMUM TOLERATED DOSE; META ANALYSIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE;

EID: 84877904767     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012458480     Document Type: Review

References (49)

1. Alberts S. Fitch T. Kim G. Morlan B. Dakhil S. Gross H. et al. (2011) Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol, in press.
2. Arora A. Scholar E. (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315: 971–979.
3. Bekaii-Saab T. Markowitz J. Prescott N. Sadee W. Heerema N. Wei L. et al. (2009) A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 15: 5895–5901.
4. Carlin C. Simon D. Mattison J. Knowles B. (1988) Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines. Mol Cell Biol 8: 25–34.
5. Chan S. Chung H. Wang L. Lim R. Picus J. Boyer M. et al. (2012) Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG). J Clin Oncol 30(Suppl. 4): abstract 259.
6. Chao Y. Li C. Chau G. Chen C. King K. Lui W. et al. (2003) Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10: 355–362.
7. Chen L. Shiah H. Chen C. Lin Y. Lin P. Su W. et al. (2009) Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 27(15 Suppl.): abstract 4587.
8. Cheng A. Kang Y. Lin D. Park J. Kudo M. Qin S. et al. (2011) Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 29(Suppl.): abstract 4000.
9. Cohn A. Kelley R. Yang T. Su W. Verslype C. Ramies D. et al. (2012) Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 30(Suppl. 4): abstract 261.
10. Faivre S. Raymond E. Boucher E. Douillard J. Lim H. Kim J. et al. (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10: 794–800.
11. Finn R. Kang Y. Mulcahy M. Polite B. Lim H. Walters I. et al. (2012) Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res, in press.
12. Gruenwald V. Wilkens L. Gebel M. Greten T.F., Kubicka S. Ganser A. et al. (2007) A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results. J Clin Oncol 25(18 Suppl.):abstract 4598.
13. Harada K. Shiota G. Kawasaki H. (1999) Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 19: 318–325.
14. Hoda D. Catherine C. Strosberg J. Valone T. Jump H. Campos T. et al (2008) Phase II study of sunitinib malate in adult pts (pts) with metastatic or surgically unresectable hepatocellular carcinoma (HCC). In: Proceedings of the 2008 Gastrointestinal Cancers Symposium, abstract 128.
15. Huynh H. Ngo V. Fargnoli J. Ayers M. Soo K. Koong H. et al. (2008) Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14: 6146–6153.
16. Huynh H. Nguyen T. Chow K. Tan P. Soo K. Tran E. (2003) Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3: 19.
17. Ito Y. Takeda T. Higashiyama S. Sakon M. Wakasa K. Tsujimoto M. et al. (2001) Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol Rep 8: 903–907.
18. Jeng K. Sheen I. Wang Y. Gu S. Chu C. Shih S. et al. (2004) Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J Gastroenterol 10: 643–648.
19. Kanai F. Yoshida H. Tateishi R. Sato S. Kawabe T. Obi S. et al. (2011) A phase I / II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 67: 315–324.
20. Kira S. Nakanishi T. Suemori S. Kitamoto M. Watanabe Y. Kajiyama G. (1997) Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver 17: 177–182.
21. Kiss A. Wang N. Xie J. Thorgeirsson S. (1997) Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met, TGF-beta receptor type II, and p 53 expression in human hepatocellular carcinomas. Clin Cancer Res 3: 1059–1066.
22. Koeberle D. Montemurro M. Samaras P. Majno P. Simcock M. Kovacs K. et al. (2009) Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): A multicenter phase II trial (SAKK 77 / 06 and SASL 23). J Clin Oncol 27(15 Suppl.): abstract 4591.
23. Koeberle D. Montemurro M. Samaras P. Majno P. Simcock M. Limacher A. et al. (2010) Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 15: 285–292.
24. Mendel D. Laird A. Xin X. Louie S. Christensen J. Li G. et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic / pharmacodynamic relationship. Clin Cancer Res 9: 327–337.
25. Messerini L. Novelli L. Comin C. (2004) Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol 57: 867–871.
26. Miura H. Miyazaki T. Kuroda M. Oka T. Machinami R. Kodama T. et al. (1997) Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 27: 854–861.
27. O'Dwyer P. Giantonio B. Levy D. Kauh J. Fitzgerald D. Ab B. (2006) Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol 24(18 Suppl.): 4143.
28. O'Neil B. Goff L. Kauh J. Strosberg J. Bekaii-Saab T. Lee R. et al. (2011) Phase II study of the mitogen-activated protein kinase 1 / 2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 29: 2350–2356.
29. Okita K. Kumada H. Ikeda K. Kudo M. Kawazoe S. Osaki Y. et al. (2012) Phase I / II study of E 7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate. J Clin Oncol 30: (Suppl. 4): abstract 320.
30. Park J. Finn R. Kim J. Karwal M. Li R. Ismail F. et al. (2011) Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 17: 1973–1983.
31. Parkin D. Bray F. Ferlay J. Pisani P. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.
32. Pawson T. (2002) Regulation and targets of receptor tyrosine kinases. Eur J Cancer 38(Suppl. 5): S3–S10.
33. Philip P. Mahoney M. Allmer C. Thomas J. Pitot H. Kim G. et al. (2005) Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23: 6657–6663.
34. Poon R. Ho J. Tong C. Lau C. Ng I. Fan S. (2004) Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91: 1354–1360.
35. Ramanathan R. Belani C. Singh D. Tanaka M. Lenz H. Yen Y. et al. (2009) A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 64: 777–783.
36. Siegel A. Cohen E. Ocean A. Lehrer D. Goldenberg A. Knox J. et al. (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26: 2992–2998.
37. Thomas M. Chadha R. Glover K. Wang X. Morris J. Brown T. et al. (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110: 1059–1067.
38. Toh H. Chen P. Carr B. Knox J. Gill S. Steinberg J. et al. (2009) A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis. J Clin Oncol 27(15 Suppl.): abstract 4581.
39. Villanueva A. Chiang D. Newell P. Peix J. Thung S. Alsinet C. et al. (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135: 1972–1983, 1983, e1971–e1911
40. Wedge S. Kendrew J. Hennequin L. Valentine P. Barry S. Brave S. et al. (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65: 4389–4400.
41. Yamaguchi R. Yano H. Iemura A. Ogasawara S. Haramaki M. Kojiro M. (1998) Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28: 68–77.
42. Yamaguchi R. Yano H. Nakashima Y. Ogasawara S. Higaki K. Akiba J. et al. (2000) Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 7: 725–729.
43. Yau T. Chen P. Chan P. Curtis C. Murphy P. Suttle A. et al. (2011) Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res 17: 6914–6923.
44. Yeh Y. Tsai J. Chuang L. Yeh H. Tsai J. Florine D. et al. (1987) Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res 47: 896–901.
45. Zhu A. Abrams T. Miksad R. Blaszkowsky L. Meyerhardt J. Zheng H. et al. (2011 a) Phase 1 / 2 study of everolimus in advanced hepatocellular carcinoma. Cancer 117: 5094–5102.
46. Zhu A. Duda D. Sahani D. Jain R. (2011 b) HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 8: 292–301.
47. Zhu A. Finn R. Mulcahy M. Gurtler J. Sun W. Schwartz J. et al. (2010) A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 28(15 Suppl.): abstract 4083.
48. Zhu A. Sahani D. Duda D. di Tomaso E. Ancukiewicz M. Catalano O. et al. (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27: 3027–3035.
49. Zhu A. Stuart K. Blaszkowsky L. Muzikansky A. Reitberg D. Clark J. et al. (2007) Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110: 581–589.